Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
1.160
+0.040 (3.57%)
At close: May 28, 2025, 4:00 PM
1.169
+0.009 (0.77%)
After-hours: May 28, 2025, 5:46 PM EDT
Gossamer Bio Employees
As of December 31, 2024, Gossamer Bio had 145 total employees, including 144 full-time and 1 part-time employees. The number of employees increased by 10 or 7.41% compared to the previous year.
Employees
145
Change (1Y)
10
Growth (1Y)
7.41%
Revenue / Employee
$859,241
Profits / Employee
-$353,366
Market Cap
263.67M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
GOSS News
- 12 days ago - Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 13 days ago - Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Business Wire
- 16 days ago - Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 - Business Wire
- 21 days ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference - Business Wire
- 2 months ago - Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - Business Wire
- 3 months ago - Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD - Seeking Alpha
- 4 months ago - Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress - Business Wire